Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Eli Lilly Japan Applies for Strattera Oral Solution
September 19, 2012
- 60% of Sales to Come from Specialty Field, Oncology by 2017: President Mitani of Novartis Pharma
September 19, 2012
- Janssen Pharmaceutical Discontinues PII Study for Atopic Dermatitis Treatment in Japan
September 19, 2012
- Eisai to Push Efficacy of Careram in Combination with MTX, Low Drug Costs
September 19, 2012
- MTPC, Daiichi Sankyo Conduct Largest Ever Copromotion for Tenelia, Aiming for Top Position in Diabetes Market with SGLT-2 Inhibitor
September 19, 2012
- Teva Appoints Itzhak Krinsky as Chairman for Japan, South Korea
September 18, 2012
- Chugai Provides All-Case PMS Data via iPad, Beginning with Avastin
September 18, 2012
- Kaketsuken Starts PIII Trial for Cell-Culture-Based New-Type Influenza Vaccine
September 18, 2012
- Astellas Launches Enzalutamide in the US
September 18, 2012
- 100,000 Registrations Expected by End of Year on Japan Vaccine’s Mobile Phone Vaccination Website
September 18, 2012
- Kyowa Kirin to Return Rights for Busulfex in Japan and Asia to Otsuka
September 18, 2012
- Detailing with iPad Rapidly Increases, Up 21.6 Points to 48.8%: Doctor Survey
September 14, 2012
- JT Sees Silver Lining in Pharmaceutical Biz 25 Yrs after Market Entry; 1st Approval Obtained for Proprietary Drug
September 14, 2012
- Eisai Ties up with US NPO to Support Vaccine Development for Tropical Diseases
September 14, 2012
- Eisai Launches Next Mainstay Product in Europe; Antiepileptic Perampanel
September 14, 2012
- MTPC Files for Additional Indication of Chronic Atrial Fibrillation for Maintate
September 14, 2012
- Bayer Yakuhin Granted Priority Review for NDA for Regorafenib
September 13, 2012
- Takeda Completes New Russian Factory, Full-Scale Operation Scheduled in 2014
September 13, 2012
- FDA Accepts Resubmission of NDA for Once-Monthly Aripiprazole Injection: Otsuka
September 13, 2012
- Pfizer Japan Files Add’l Indication of MS for Solu-Medrol Based on Data from Public Domain
September 13, 2012
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…